SCHEMBL8964944

SCHEMBL8964944

COc1ccc(/C=C/C(=O)c2ccc(O)cc2)cc1C

nearest known ligand 0.80

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSL P07711 3/20 0.74
MEN1 O00255 3/20 0.69
KMT2A Q03164 3/20 0.69
ABCG2 Q9UNQ0 3/20 0.69
CA1 P00915 2/20 0.67
CA2 P00918 2/20 0.67
CAPN1 P07384 2/20 0.64
CXCL12 P48061 3/20 0.64
MAPT P10636 3/20 0.63
ALDH1A1 P00352 2/20 0.63
P4HB P07237 1/20 0.63
CALM1 P0DP23 1/20 0.63
RAB9A P51151 1/20 0.63
F3 P13726 1/20 0.63
XDH P47989 1/20 0.63
LMNA P02545 1/20 0.63
TNFRSF1A P19438 1/20 0.63
CTSB P07858 2/20 0.61
TDP1 Q9NUW8 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8964940 1.00 CTSL (0.74) CTSLMEN1KMT2AABCG2CA1
SCHEMBL31233066 1.00 CTSL (0.74) CTSLMEN1KMT2AABCG2CA1
SCHEMBL8977079 0.92 ABCG2 (0.69) CTSLMEN1KMT2AABCG2CA1
SCHEMBL8977076 0.92 ABCG2 (0.69) CTSLMEN1KMT2AABCG2CA1
SCHEMBL3263021 0.89 TNFRSF1A (0.80) MEN1KMT2AABCG2CXCL12MAPT
SCHEMBL3263018 0.89 TNFRSF1A (0.80) MEN1KMT2AABCG2CXCL12MAPT
SCHEMBL8965726 0.89 CA1 (0.70) CTSLMEN1KMT2AABCG2CA1
SCHEMBL30383073 0.89 CA1 (0.70) CTSLMEN1KMT2AABCG2CA1
SCHEMBL8965729 0.89 CA1 (0.70) CTSLMEN1KMT2AABCG2CA1
SCHEMBL25199646 0.89 ABCG2 (0.88) CTSLMEN1KMT2AABCG2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
US-5525457-A Copolymers of unsaturated carboxylic acid, an epoxy-functional monomer, and cinnamoylphenyl group-monomer; high halation preventing effect, involves no sublimation of radiation absorbing components contained therein, possesses excellent heat resistance, dry etching performance, storage stability JAPAN SYNTHETIC RUBBER CO., LTD. (JP) 1996-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B CTSL 357/4885MEN1 3367/4885KMT2A 2792/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 CTSL 310/4885MEN1 2457/4885KMT2A 3188/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 CTSL 310/4885MEN1 2457/4885KMT2A 3188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.